8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K
                                 CURRENT REPORT

                         PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934



         Date of Report (Date of earliest event reported): June 19, 2002



                             ViroPharma Incorporated
                 (Exact name of issuer as specified in charter)



            DELAWARE                   0-021699               23-2789550
  (State or Other Jurisdiction        (Commission          (I.R.S. Employer
       of Incorporation or                file               Identification
          Organization)                 number)                 Number)


                             405 EAGLEVIEW BOULEVARD
                            EXTON, PENNSYLVANIA 19341
                    (Address of principal executive offices)


                                 (610) 458-7300
              (Registrant's telephone number, including area code)



Item 5 - Other Events.


As is more fully described in the attached press release that is incorporated
herein by reference, on June 19, 2002, ViroPharma Incorporated announced the
extension of the screening phase of its HCV drug discovery, development and
commercialization agreement with Wyeth for up to an additional two years.

Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.

(c)      Exhibits

         Exhibit No.      Description
         -----------      -----------

             99           ViroPharma Incorporated Press Release dated June 19,
                          2002

                                   Signatures

             Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.

                                   ViroPharma Incorporated


Date: June 24, 2002                By: /s/ Thomas F. Doyle
                                       -------------------
                                   Thomas F. Doyle
                                   Vice President, General Counsel and Secretary



                                Index to Exhibits

Exhibit No.          Description
- -----------          -----------

    99               ViroPharma Incorporated Press Release dated June 19, 2002

EX-99

                                                                      Exhibit 99

[LOGO] [LETTERHEAD OF VIROPHARMA
                    INCORPORATED]

                        ViroPharma Announces Extension of
             Hepatitis C Screening Phase of Collaboration with Wyeth

Exton, PA, June 19, 2002 - ViroPharma Incorporated (Nasdaq: VPHM), today
announced that it has extended the screening phase of its HCV drug discovery,
development and commercialization agreement with Wyeth (NYSE: WYE) for up to an
additional two years.

The companies are engaged in a broad-based program designed to discover, develop
and commercialize antiviral compounds to treat hepatitis C. Under the terms of
the agreement, signed in December 1999, Wyeth pays a substantial portion of HCV
research and development expenses incurred by ViroPharma. The companies will
co-promote products resulting from the collaboration and share equally in
profits from product sales in the U.S. and Canada. In the rest of the world,
Wyeth will assume full responsibility for commercialization of products and will
pay to ViroPharma royalties on product sales.

 "We have made significant advancements in our hepatitis C program with Wyeth,"
said Michel de Rosen, ViroPharma's president and chief executive officer. "Both
companies now have access to some of the newest technologies in the HCV area,
which we expect will improve our chances for success. We are planning to advance
our next lead compound into phase 1 safety studies by the end of this year. We
also are advancing several additional compounds in earlier stages of
development."

"The hepatitis C effort represents an important program for Wyeth," said L.
Patrick Gage, Ph.D., Wyeth's president of research. "Together with ViroPharma,
we have set an aggressive timeline for advancing new antiviral drug candidates
that one day could dramatically improve the lives of people who suffer from
hepatitis C."



Hepatitis C virus is recognized as a major cause of chronic hepatitis worldwide.
Approximately 85 percent of persons infected with HCV develop chronic hepatitis,
of which 20 percent progress to liver cirrhosis. Hepatitis C affects more than
170 million people worldwide and accounts for approximately 40 percent of all
deaths due to liver failure, or about 10,000 deaths each year, according to the
Centers for Disease Control and Prevention.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the commercialization, development and
discovery of antiviral pharmaceuticals. ViroPharma is focused on drug
development and discovery activities in viral diseases including the common cold
(a viral respiratory infection, or VRI), hepatitis C and RSV disease.
ViroPharma's most advanced product candidate, Picovir(TM), is in clinical
development for the treatment of picornavirus diseases, and was the subject of a
new drug application (NDA) that was reviewed by the FDA for the treatment of VRI
in adults. In May 2002, ViroPharma received a "not approvable" letter from the
FDA with respect to the Picovir NDA. ViroPharma also has product candidates in
preclinical and clinical development for the treatment of hepatitis C and RSV
diseases, respectively. ViroPharma's sales force currently details two drugs for
Aventis Pharmaceuticals.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health
care products companies. It is a leader in the discovery, development,
manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology
products and non-prescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth Pharmaceuticals,
Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Statements in this press release relating to ViroPharma's plans and efforts to
develop product candidates for the treatment of hepatitis C, plans for advancing
hepatitis C product candidates into clinical trials and the ability of new
technologies to improve ViroPharma's likelihood for success in its HCV program
are forward-looking and subject to risks and uncertainties. The discovery and
development of investigational pharmaceutical products is subject to risks and
uncertainties. There can be no assurance that appropriate HCV product
development candidates can be identified, that planned clinical studies can be
initiated in accordance with ViroPharma's anticipated schedule or at



all, that technologies to which ViroPharma has access will improve ViroPharma's
likelihood for success in its HCV program. These factors, and other factors,
including, but not limited to those described in ViroPharma's most recent annual
report on Form 10-K and quarterly report on Form 10-Q filed with the Securities
and Exchange Commission, could cause future results to differ materially from
the expectations expressed in this press release. The forward-looking statements
contained in this press release may become outdated over time. ViroPharma does
not assume any responsibility for updating any forward-looking statements.

                                      # # #